{"count": 4, "results": [{"_id": "22096395", "pmid": 22096395, "pmcid": "PMC3218685", "title": "New and emerging agents in the management of lipodystrophy in HIV-infected patients", "journal": "HIV AIDS (Auckl)", "authors": ["Bonnet E"], "date": "2010-01-01T00:00:00Z", "doi": "10.2147/HIV.S13429", "meta_date_publication": "2010", "meta_volume": "2", "meta_issue": "", "meta_pages": "167-78", "score": 50101.5, "text_hl": "Regarding lipohypertrophy, diet and exercise, recombinant @SPECIES_9606 @@@human@@@ @GENE_GH1 @GENE_2688 @@@growth hormone@@@, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may reduce visceral fat, but may worsen subcutaneous @<m>DISEASE_Lipoatrophy_with_diabetes_hepatic_steatosis_cardiomyopathy_and_leukomelanodermic_papules</m> @DISEASE_MESH:C535905 @@@lipoatrophy@@@. ", "citations": {"NLM": "Bonnet E. New and emerging agents in the management of lipodystrophy in HIV-infected patients HIV AIDS (Auckl). 2010;2():167-78. PMID: 22096395", "BibTeX": "@article{22096395, title={New and emerging agents in the management of lipodystrophy in HIV-infected patients}, author={Bonnet E}, journal={HIV AIDS (Auckl)}, volume={2}, pages={167-78}}"}}, {"_id": "17504362", "pmid": 17504362, "title": "Long-term complications of antiretroviral therapy: lipoatrophy.", "journal": "Int J Clin Pract", "authors": ["Waters L", "Nelson M"], "date": "2007-06-01T00:00:00Z", "doi": "10.1111/j.1742-1241.2007.01385.x", "meta_date_publication": "2007 Jun", "meta_volume": "61", "meta_issue": "6", "meta_pages": "999-1014", "score": 50070.85, "text_hl": "@DISEASE_Persistent_Infection @DISEASE_MESH:D000088562 @@@Long-term complications@@@ of antiretroviral therapy: @<m>DISEASE_Lipoatrophy_with_diabetes_hepatic_steatosis_cardiomyopathy_and_leukomelanodermic_papules</m> @DISEASE_MESH:C535905 @@@lipoatrophy@@@.", "citations": {"NLM": "Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract. 2007 Jun;61(6):999-1014. PMID: 17504362", "BibTeX": "@article{17504362, title={Long-term complications of antiretroviral therapy: lipoatrophy.}, author={Waters L and Nelson M}, journal={Int J Clin Pract}, volume={61}, number={6}, pages={999-1014}}"}}, {"_id": "19372908", "pmid": 19372908, "title": "Treatment strategies for HIV lipodystrophy.", "journal": "Curr Opin HIV AIDS", "authors": ["Carr A"], "date": "2007-07-01T00:00:00Z", "doi": "10.1097/COH.0b013e3281df2b57", "meta_date_publication": "2007 Jul", "meta_volume": "2", "meta_issue": "4", "meta_pages": "332-8", "score": 50061.69, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and @GENE_GH1 @GENE_2688 @@@growth hormone@@@ and its analogues are effective in reducing @DISEASE_Abdominal_Injuries @DISEASE_MESH:D000007 @@@abdominal fat accumulation@@@, although they aggravate @<m>DISEASE_Lipoatrophy_with_diabetes_hepatic_steatosis_cardiomyopathy_and_leukomelanodermic_papules</m> @DISEASE_MESH:C535905 @@@lipoatrophy@@@ and generally have only transient effects. ", "citations": {"NLM": "Carr A. Treatment strategies for HIV lipodystrophy. Curr Opin HIV AIDS. 2007 Jul;2(4):332-8. PMID: 19372908", "BibTeX": "@article{19372908, title={Treatment strategies for HIV lipodystrophy.}, author={Carr A}, journal={Curr Opin HIV AIDS}, volume={2}, number={4}, pages={332-8}}"}}, {"_id": "18685115", "pmid": 18685115, "title": "Approach to the human immunodeficiency virus-infected patient with lipodystrophy.", "journal": "J Clin Endocrinol Metab", "authors": ["Brown TT"], "date": "2008-08-01T00:00:00Z", "doi": "10.1210/jc.2008-1019", "meta_date_publication": "2008 Aug", "meta_volume": "93", "meta_issue": "8", "meta_pages": "2937-45", "score": 50040.094, "text_hl": "Treatment of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@ in @DISEASE_HIV_Infections @DISEASE_MESH:D015658 @@@HIV-infected@@@ @SPECIES_9606 @@@patients@@@ should generally follow established guidelines, but @CHEMICAL_Thiazolidinediones @CHEMICAL_MESH:D045162 @@@thiazolidinediones@@@, rather than @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, may be considered first-line treatment in a @SPECIES_9606 @@@patient@@@ with @<m>DISEASE_Lipoatrophy_with_diabetes_hepatic_steatosis_cardiomyopathy_and_leukomelanodermic_papules</m> @DISEASE_MESH:C535905 @@@lipoatrophy@@@, given their potential to increase sc fat. ", "citations": {"NLM": "Brown TT. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J Clin Endocrinol Metab. 2008 Aug;93(8):2937-45. PMID: 18685115", "BibTeX": "@article{18685115, title={Approach to the human immunodeficiency virus-infected patient with lipodystrophy.}, author={Brown TT}, journal={J Clin Endocrinol Metab}, volume={93}, number={8}, pages={2937-45}}"}}]}